(±)-Forbesione
(±)-Forbesione, a potential apoptosis inducer, is a racemate of Forbesione (HY-N7892). (±)-Forbesione inhibits proliferation of cancer cells. (±)-Forbesione can be used for cancer research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- CAS. Nr.: 667914-50-3
- Formel: C28H32O6
- Molecular Weight:464.55
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biologische Aktivität
Beschreibung
In Vitro
(±)-Forbesione (range of concentrations; 24 h) exhibits low micromolar antiproliferative activity against HepG2, A549, and U251 cells, with IC50 values of 4.07 μM, 3.58 μM, and 8.57 μM, respectively[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:Ham-1 cholangiocarcinoma cells
-
Concentration:0.5 µM; 1 µM; 2 µM; 4 µM; 8 µM
-
Incubation Time:24 h
-
Result:Induced concentration-dependent S-phase cell cycle arrest (P<0.01).
Reduced the proportion of cells in the G0/G1 (P<0.05) and G2/M (P<0.05) phases.
Increased the percentage of cells in the sub-G1 fraction (apoptotic cells) significantly in a concentration-dependent manner (P<0.01).
-
Cell Line:Ham-1 cholangiocarcinoma cells
-
Concentration:2 µM; 4 µM; 8 µM; 16 µM
-
Incubation Time:24 h
-
Result:Induced bright green, condensed, and fragmented chromatin, which are hallmarks of apoptosis, in treated cells, while untreated cells showed uniformly green-stained, normal nuclei.
-
Cell Line:Ham-1 cholangiocarcinoma cells
-
Concentration:2 µM; 4 µM; 8 µM; 16 µM; 32 μM
-
Incubation Time:6, 24, 48 h
-
Result:Increased the percentage of apoptotic cells in a concentration- and time-dependent manner.
Resulted in 50.75% (P<0.01), 55.57% (P<0.001), and 64.43% (P<0.001) apoptotic cells at 6, 24, and 48 h respectively when treated with 32 µM.
-
Cell Line:Ham-1 cholangiocarcinoma cells
-
Concentration:2 µM; 4 µM; 8 µM
-
Incubation Time:24 h
-
Result:Significantly decreased protein expression of cyclin E (P<0.01), cyclin A (P<0.05), and cyclin-dependent kinase 2 (Cdk2) (P<0.01).
Significantly increased protein expression of p21 (P<0.05) and p27 (P<0.05) compared to control cells.\nIncreased protein expression of Fas (P<0.05), Fas-associated death domain (FADD) (P<0.05), and activated caspase-3 (P<0.05) in the death receptor pathway.
Decreased protein expression of procaspase-8 (P<0.05) and procaspase-3 (P<0.01) in the death receptor pathway.
Increased protein expression of B-cell lymphoma-2-like protein 4 (Bax) (P<0.05), activated caspase-9 (P<0.05), and activated caspase-3 (P<0.05) in the mitochondrial pathway.
Decreased protein expression of B-cell lymphoma-2 (Bcl-2) (P<0.05), procaspase-9 (P<0.05), and procaspase-3 (P<0.01) in the mitochondrial pathway.
Increased protein expression of activated caspase-12 (P<0.05), activated caspase-9 (P<0.05), and activated caspase-3 (P<0.05) in the endoplasmic reticulum pathway.
Decreased protein expression of procaspase-12 (P<0.05), procaspase-9 (P<0.05), and procaspase-3 (P<0.01) in the endoplasmic reticulum pathway.\nSignificantly decreased protein expression of NF-κB/p65 (P<0.01) compared to control cells.
Significantly increased protein expression of inhibitor of κB-α (IκB-α) (P<0.05) compared to control cells.\nSignificantly decreased protein expression of cytokeratin 19 (CK19) (P<0.01) compared to control cells.
Significantly decreased protein expression of proliferating cell nuclear antigen (PCNA) (P<0.05) compared to control cells.
-
Cell Line:human cholangiocarcinoma KKU-100 cells
-
Concentration:0.25 µM; 0.5 µM; 1 µM; 2 μM; 1 μM (combined with 0.025 μM Doxorubicin)
-
Incubation Time:48 h
-
Result:Increased apoptosis in KKU-100 cells in a dose-dependent manner, with the highest single-agent dose (2 μM) inducing ~32% apoptotic cells.
Induced ~75% apoptotic cells when combined with 0.025 μM Doxorubicin, which was significantly higher than either single agent alone.
-
Cell Line:human cholangiocarcinoma KKU-100 cells
-
Concentration:0.25 μM; 0.5 μM; 1 μM (single agent); 0.25 μM + 0.006 μM Doxorubicin (C1); 0.5 μM + 0.012 μM Doxorubicin (C2); 1 μM + 0.025 μM Doxorubicin (C3)
-
Incubation Time:48 h
-
Result:Decreased Bcl-2 expression (0.27-fold at 1 μM) and increased Bax expression (2.06-fold at 1 μM) as a single agent, leading to a Bax/Bcl-2 ratio of 1.63; the C3 combination further decreased Bcl-2 to 0.10-fold and increased Bax to 3.24-fold, resulting in a Bax/Bcl-2 ratio of 12.00.
Decreased survivin (0.35-fold at 1 μM), procaspase-9 (0.70-fold at 1 μM), and procaspase-3 (0.76-fold at 1 μM) while increasing activated caspase-9 (42.00-fold at 1 μM) and activated caspase-3 (42.00-fold at 1 μM) as a single agent; the C3 combination enhanced these effects, reducing procaspase-9 and procaspase-3 to 0-fold and increasing activated caspase-9 and caspase-3 to 64.00-fold and 54.00-fold, respectively.
Increased IκB-α (1.15-fold at 1 μM) and decreased pIκB-α (0.14-fold at 1 μM) and NF-κB/p65 (0.12-fold at 1 μM) as a single agent; the C3 combination further increased IκB-α to 1.21-fold and decreased pIκB-α and NF-κB/p65 to 0.01-fold each.
Decreased MRP1 expression (0.71-fold at 1 μM) as a single agent, while the C3 combination reduced MRP1 to 0.34-fold, a significantly greater effect than single-agent treatment.
In Vivo
-
Animal Model:Syrian hamsters (male, 6-8 weeks old, intradermal injection of 2.5×105 Ham-1 cholangiocarcinoma cells)[1]
-
Dosage:50 mg/kg
-
Administration:p.o.; daily; 4 weeks
-
Result:Reduced tumor volume (P<0.01) and mean tumor weight from 0.54 g (control) to 0.27 g (P<0.001).
Significantly decreased relative CK19 mRNA expression in tumor tissues (P<0.05).
Significantly increased relative Bax, Apaf-1, caspase-9, and caspase-3 mRNA expression in tumor tissues (P<0.05).
Significantly decreased expression of CK19 (P=0.036), PCNA (P=0.032), cyclin A (P=0.028), and Bcl-2 (P=0.039) in tumor tissues via immunohistochemical analysis.
Significantly increased expression of Bax (P=0.039), caspase-9 (P=0.028), and caspase-3 (P=0.039) in tumor tissues via immunohistochemical analysis.
Increased body weight (P<0.001), food intake (P<0.001), and water intake (P<0.05) in treated hamsters.
Caused no significant histopathological changes in liver, kidney, or stomach, and no changes in serum liver (ALT, ALP) or kidney (BUN, creatinine) function markers.
Chemical Information
-
CAS. Nr. 667914-50-3
-
Molecular Weight 464.55
-
Formel C28H32O6
-
SMILES
C/C(C)=C\CC1(O2)C(C(C3)C2(C)C)(OC4=C(C(O)=C5)C/C=C(C)\C)C(C(C4=C5O)=O)=CC3C1=O
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Protokoll
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Reinheit & Dokumentation
Verweise
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)